Methyl Protect 120 C

Methyl Protect 120 C by Xymogen

Methyl Protect 120 capsules is a multi-vitamin supplement designed by Xymogen.* It may have a plethora of effects, from supporting your cardiovascular health, to promoting antioxidation and cellular energy production.* This makes Methyl Protect 120c a versatile supplement that you may take for multiple purposes.*

Who Should Consider Methyl Protect 120 Capsules by Xymogen?

Methyl Protect 120c may support your health if:

• you struggle with elevated homocysteine levels*
• you want to improve memory, focus and overall cognitive function*
• you often feel fatigue*
• you want to support your general health and wellness*

What Effects May Methyl Protect 120c Have on Your Body?

Methyl Protect 120c may:

• support your cardiovascular system*
• help you maintain healthy homocysteine levels if already within normal range*
• promote healthy methylation of:
• estrogen*
• dopamine*
• epinephrine*
• heavy metals*
• environmental toxins*

Supplements support your health but do not replace a balanced diet. Always check with your healthcare practitioner if you have doubts about a new supplement. Book a FREE product consultation to learn more about Methyl Protect 120c by Xymogen.

Recommendation: 
Take one capsule one to two times daily, or as directed by your healthcare professional.

Serving Size: 1 capsule
Servings Per Container: 120

Amount Per Serving:
Riboflavin (as riboflavin 5’-phosphate sodium) 25 mg
Vitamin B6 (as pyridoxal 5’-phosphate) 10 mg
Folate (1,700 mcg DFE as calcium folinate and 1,700 mcg DFE as (6S)-5
methyltetrahydrofolic acid, glucosamine saltS1) 3,400 mcg
Vitamin B12 (as methylcobalamin) 1,000 mcg
Betaine Anhydrous (trimethylglycine) 500 mg

Other Ingredients: Capsule (hypromellose and water), stearic acid, microcrystalline cellulose, silica, magnesium stearate, and medium-chain triglyceride oil.

Does Not Contain: Wheat, gluten, corn, yeast, soy, animal and dairy products, fish, shellfish, peanuts, tree nuts, egg, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, and artificial preservatives.

Warning:
Consult your healthcare professional prior to use. Individuals taking medication should discuss potential interactions with their healthcare professional.

Storage:
Keep closed in a cool, dry place out of reach of children.

*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Trademarks:
S1. Quatrefolic^® is a registered trademark of Gnosis S.p.A. Produced under US patent 7,947,662.


Click here to view Data Sheet

LEGAL NOTICE: Xymogen's Exclusive Professional Formulas are available through select licensed health care professionals. The Internet Sale and Discounting of XYMOGEN formulas are strictly prohibited. covenanthealthproducts.com makes XYMOGEN formulas available only to patients of our clinic. If you are a patient of covenanthealthproducts.com, you may inquire about XYMOGEN by calling (800) 627-6518

References:

1. Caruso, R., Campolo, J., Sedda, V., et al. (2006). Effect of homocysteine lowering by 5-methyltetrahydrofolate on redox status in hyperhomocysteinemia. Journal of Cardiovascular Pharmacology, 47(4), 549–555. [PMID: 16680068]
2. Go, E. K., Jung, K. J., Kim, J. Y., et al. (2005). Betaine suppresses proinflammatory signaling during aging: The involvement of nuclear factor-kappaB via nuclear factor-inducing kinase/IkappaB kinase and mitogen-activated protein kinases. Journal of Gerontology A: Biological Sciences and Medical Sciences, 60(10), 1252–1264. [PMID: 16282556]
3. Halsted, C. H., Villanueva, J. A., Devlin, A. M., et al. (2002). Folate deficiency, methionine metabolism, and alcoholic liver disease. Alcohol, 27(3), 169–172. [PMID: 12163145]
4. Homocysteine Lowering Trialists’ Collaboration. (1998). Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. BMJ, 316(7135), 894–898. [PMID: 9569395]
5. Kluijtmans, L. A., Van den Heuvel, L. P., Boers, G. H., et al. (1996). Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. American Journal of Human Genetics, 58(1), 35–41. [PMID: 8554066]
6. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists’ Collaboration. (1998). BMJ. 316(7135): 894–898. [PMID: 9569395]
7. Moat, S. J., Ashfield-Watt, P. A., Powers, H. J., et al. (2003). Effect of riboflavin status on the homocysteine-lowering effect of folate in relation to the MTHFR (C677T) genotype. Clinical Chemistry, 49(2), 295–302. [PMID: 12560354]
8. Selhub, J. (2006). The many facets of hyperhomocysteinemia: Studies from the Framingham cohorts. Journal of Nutrition, 136(6 Suppl), 1726S–1730S. [PMID: 16702347]
9. Strain, J. J., Dowey, L., Ward, M., et al. (2004). B-vitamins, homocysteine metabolism and cardiovascular disease. Proceedings of the Nutrition Society, 63(4), 597–603. [PMID: 15831132]
10. Venn, B. J., Green, T. J., Moser, R., et al. (2003). Comparison of the effect of low-dose supplementation with L-5-methyltetrahydrofolate or folic acid on plasma homocysteine: A randomized placebo-controlled study. American Journal of Clinical Nutrition, 77(3), 658–662. [PMID: 12600857]
11. Yakut, M., Ustün, Y., Kabaçam, G., et al. (2010). Serum vitamin B(12) and folate status in patients with inflammatory bowel diseases. European Journal of Internal Medicine, 21(4), 320–323. [PMID: 20603044]